PFI-3

• UNSPSC Description:

  PFI-3 is a selective, potent and cell-permeable SMARCA2/4 bromodomain inhibitor with a Kd of 89 nM.

• Target Antigen:

  Epigenetic Reader Domain

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pfi-3.html

• Purity:

  99.63

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  OC1=C(C(/C=C/N2[C@H](C3)CN(C4=NC=CC=C4)[C@H]3C2)=O)C=CC=C1

• Molecular Weight:

  321.37

• References & Citations:

  [1]Vangamudi B, et al. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies. Cancer Res. 2015 Sep 15;75(18):3865-78.|[2]Fedorov O, et al. Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance. Sci Adv. 2015 Nov 13;1(10):e1500723.|[3]Gerstenberger BS, et al. Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit. J Med Chem. 2016 May 26;59(10):4800-11.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1819363-80-8